A Phase 4 interventional study of 5% dextrose prolotherapy and Dry needling in Temporomandibular Disorders (TMDs) and Myalgia of Mastication Muscle, sponsored by Universidad de Los Andes, Venezuela. Completed at 1 site in Venezuela. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Universidad de Los Andes, Venezuela · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial was to compare the pain-relieving effect of prolotherapy with 5% dextrose and dry needling in adults with local myalgia of the masseter muscle, a type of temporomandibular disorder (TMD). The main questions it aimed to answer were:
Participants were randomly assigned to one of two groups and received a single treatment session on the trigger points of the masseter muscles:
Pain intensity and the number of trigger points were assessed before treatment, immediately after treatment, at 72 hours and at 15 days. Participants were asked to report any adverse event during follow-up.
This was a randomized, parallel-group clinical trial with 1:1 allocation, conducted at the Faculty of Dentistry, Universidad de Los Andes (Mérida, Venezuela), in accordance with the Declaration of Helsinki and the CONSORT statement. The trial was registered retrospectively.
Diagnosis of local myalgia was established by calibrated examiners according to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD), using the TMD Symptom Questionnaire and the TMD Clinical Examination Form. A pilot test with four patients, not included in the final sample, was performed to assess feasibility and to calibrate the operator.
The sample size was calculated with G*Power 3.1.9.7 for a repeated-measures ANOVA with a treatment x time interaction (alpha = 0.05, power = 80%, f = 0.35, four measurements, correlation among measurements r = 0.50, nonsphericity correction = 1), yielding a minimum of 20 participants. Twenty-three participants were enrolled.
The allocation sequence was generated with Research Randomizer and concealed by an external collaborator not involved in clinical care. Masking of the operator and participants was not possible. The statistician was blinded to group allocation.
Trigger points in both masseter muscles were identified by digital palpation with approximately 1 kg of pressure for at least 2 seconds and marked on the skin. Prolotherapy was performed with a 31G needle and an insulin syringe, with a single insertion per trigger point. Dry needling was performed with sterile 0.25 mm acupuncture needles using Hong's fast-in, fast-out technique. All sessions lasted approximately 30 minutes. Participants were asked to avoid analgesics, physiotherapy, occlusal splints and self-medication during follow-up.
Adverse events were assessed according to CONSORT Harms 2022 and classified by MedDRA System Organ Class.
593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
This study's enrollment of 23 is below the median of 45 across 417 interventional studies indexed under Temporomandibular Joint Disorders.
Browse Temporomandibular Joint Disorders studies →This is the only study on the registry with Universidad de Los Andes, Venezuela as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single session. Injection of 0.5 mL of 5% dextrose into each trigger point of both masseter muscles, with a 31G needle and a single insertion per trigger point.
Drug: 5% dextrose prolotherapy
Single session. Dry needling of each trigger point of both masseter muscles with 0.25 mm sterile acupuncture needles, using Hong's fast-in, fast-out technique, without injecting any substance.
Procedure: Dry needling
Injection of 0.5 mL of 5% dextrose solution into each identified trigger point
Repeated fast-in, fast-out needling of each identified trigger point without injectate.
Change in Pain Intensity Immediately After Treatment
Pain intensity measured with a 0-10 Visual Analogue Scale (VAS; 0 = no pain, 10 = worst pain), expressed as the mean of both sides of the face. Change calculated as post-treatment minus baseline; negative values indicate pain reduction.
Time frame: Baseline and immediately after treatment
Change in Pain Intensity at 72 Hours
0-10 VAS, mean of both sides of the face. Change from baseline; negative values indicate pain reduction.
Time frame: Baseline and 72 hours after treatment
Change in Pain Intensity at 15 Days
0-10 VAS, mean of both sides of the face. Change from baseline; negative values indicate pain reduction
Time frame: Baseline and 15 days after treatment
Change in Number of Trigger Points
Total number of trigger points in both masseter muscles identified by digital palpation according to DC/TMD. Change from baseline; negative values indicate a reduction
Time frame: Baseline, immediately after treatment, 72 hours and 15 days
Number of Participants With Adverse Events
Adverse events identified by active questioning at each visit and spontaneous reports, classified by MedDRA System Organ Class and characterized by type, severity and relationship to treatment.
Time frame: From treatment to 15 day
Plan to share: Yes — De-identified individual participant data on pain intensity (VAS), number of trigger points, adverse events and sex will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Available from the publication of the study results, with no end date.
Access criteria: Data and supporting documents will be available upon reasonable request to the principal investigator by email.
Ran from Jul 2026 to primary completion in Jul 2026, 0 months.
Of 11 phase 4 interventional studies under Temporomandibular Joint Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 23. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temporomandibular Joint Disorders →